文献速递冠心病血脂与心血管预防

基因增强脂蛋白脂肪酶介导的脂解与低密度脂蛋白胆固醇降低等位基因与冠心病及2型糖尿病风险的关联

Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
PubMed 文献 · JAMA Cardiol · 2018-01-01

结果显示LPL甘油三酯降低等位基因与冠心病风险降低约40%、2型糖尿病风险降低约30%相关,且独立于LDL-C降低机制。

要点

  • LPL通路甘油三酯降低等位基因与冠心病风险降低约40%相关,独立于LDL-C降低机制。
  • LPL通路甘油三酯降低等位基因与2型糖尿病风险降低约30%相关。
  • ANGPTL3功能丧失变异在相同LDL-C差异下,冠心病保护作用强于其他LDL-C降低机制。

核心结论

  • LPL通路甘油三酯降低等位基因与冠心病和2型糖尿病风险降低相关,且独立于LDL-C降低遗传机制。
  • 这些发现支持开发增强LPL介导脂解的药物,以在LDL-C降低治疗之外提供进一步临床获益。

研究设计与样本

  • 数据收集于1991年1月至2018年7月,分析于2014年7月至2018年7月。

主要发现

  • LPL甘油三酯降低等位基因与冠心病风险降低约40%(每SD遗传性甘油三酯降低)相关,与2型糖尿病风险降低约30%相关。
  • 在LDL-C降低等位基因分布的五分位组及2×2析因遗传分析中,上述关联一致。
  • ANGPTL4的40Lys变异在遗传性LDL-C较高或较低组中均与冠心病和2型糖尿病风险降低相关。

关键数值与推荐

  • LPL甘油三酯降低等位基因:冠心病风险降低约40%/SD,2型糖尿病风险降低约30%。

临床怎么用

  • 遗传学证据支持在LDL-C降低治疗基础上,开发增强LPL介导脂解的药物以进一步降低冠心病和2型糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs would require large outcome trials. Human genetics studies can help prioritize or deprioritize these resource-demanding endeavors. OBJECTIVE: To investigate the independent and combined associations of genetically determined differences in LPL-mediated lipolysis and low-density lipoprotein cholesterol (LDL-C) metabolism with risk of coronary disease and diabetes. DESIGN, SETTING, AND PARTICIPANTS: In this genetic association study, individual-level genetic data from 392 220 participants from 2 population-based cohort studies and 1 case-cohort study conducted in Europe were included. Data were collected from January 1991 to July 2018, and data were analyzed from July 2014 to July 2018. EXPOSURES: Six conditionally independent triglyceride-lowering alleles in LPL, the p.Glu40Lys variant in ANGPTL4, rare loss-of-function variants in ANGPTL3, and LDL-C-lowering polymorphisms at 58 independent genomic regions, including HMGCR, NPC1L1, and PCSK9. MAIN OUTCOMES AND MEASURES: Odds ratio for coronary artery disease and type 2 diabetes. RESULTS: Of the 392 220 participants included, 211 915 (54.0%) were female, and the mean (SD) age was 57 (8) years. Triglyceride-lowering alleles in LPL were associated with protection from coronary disease (approximately 40% lower odds per SD of genetically lower triglycerides) and type 2 diabetes (approximately 30% lower odds) in people above or below the median of the population distribution of LDL-C-lowering alleles at 58 independent genomic regions, HMGCR, NPC1L1, or PCSK9. Associations with lower risk were consistent in quintiles of the distribution of LDL-C-lowering alleles and 2 × 2 factorial genetic analyses. The 40Lys variant in ANGPTL4 was associated with protection from coronary disease and type 2 diabetes in groups with genetically higher or lower LDL-C. For a genetic difference of 0.23 SDs in LDL-C, ANGPTL3 loss-of-function variants, which also have beneficial associations with LPL lipolysis, were associated with greater protection against coronary disease than other LDL-C-lowering genetic mechanisms (ANGPTL3 loss-of-function variants: odds ratio, 0.66; 95% CI, 0.52-0.83; 58 LDL-C-lowering variants: odds ratio, 0.90; 95% CI, 0.89-0.91; P for heterogeneity = .009). CONCLUSIONS AND RELEVANCE: Triglyceride-lowering alleles in the LPL pathway are associated with lower risk of coronary disease and type 2 diabetes independently of LDL-C-lowering genetic mechanisms. These findings provide human genetics evidence to support the development of agents that enhance LPL-mediated lipolysis for further clinical benefit in addition to LDL-C-lowering therapy.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lotta LA, Stewart ID, Sharp SJ, et al. Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. JAMA Cardiol. 2018. PMID: 30326043. doi:10.1001/jamacardio.2018.2866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。